Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.510.06%
QQQ
716.700.01%
BTC/USD
78714.200.1947%
DIA
532.040.09%
GLD
408.230.05%
TLT
82.380.17%

Atea Pharmaceuticals Inc

AVIRNASDAQ
Trade with Public
Trade with Public
$5.35
-0.01-0.19%
At close: Aug 31, 5:00 PM EST
$5.35
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Atea Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atea Pharmaceuticals (AVIR).

Price Target Range — 4 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingOutperform# Analysts1Avg. Consensus PT$9Upside to Avg. PT+58.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 13, 2026Morgan StanleyMatthew HarrisonPT RaiseEqual-Weight$6→$7
Mar 9, 2026Evercore ISI GroupJonathan MillerPT RaiseOutperform$6→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10

Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.
Benzinga Newsdesk

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.
Vandana Singh

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.
Zacks

PRO
Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88

Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved